×
Back to Agenda
Cardiac Safety in Drug Development and the Critical Role of Public-Private Partnerships: The Cardiac Safety Research Consortium Model
Session Chair(s)
Rick Turner
Expert Consultant, DRT Strategies, Inc., United States
This session will discuss how the Cardiac Safety Research Consortium’s collaborative, precompetitive approach has significantly advanced the field of cardiac safety in medical product development. Industry, academia, and regulatory perspectives will be provided.
Learning Objective : Discuss the concept and implementation of Public-Private Partnerships; Recognize the importance of cardiac safety considerations throughout new drug development; Describe new approaches to regulatory science in cardiac safety.
Speaker(s)
Mitchell W. Krucoff, MD
Professor of Medicine/Cardiology, Duke University, United States
Norman Stockbridge, MD, PHD
Director, Division of Cardiology and Nephrology, OND, CDER, FDA, United States
Philip T. Sager, MD
Adjunct Professor, Stanford University, United States
Have an account?